Pfizer Opkos Ngenla to treat paediatric growth hormone deficiency receives Japanese approval

Pfizer Japan Inc. and Opko Health, Inc. announced that the next generation long-acting growth hormone injection, Ngenla (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan. Ngenla is a once-weekly long-acting recombinant human growth hormone, for the indication of short statue due to growth hormone deficiency without closed epiphyses. Ngenla provides patients with paediatric growth hormone deficiency (GHD) with a new option that reduces treatment frequency from daily injections to once-weekly injections. This approval is based on the results of a phase 3 study conducted in Japanese subjects and a global phase 3 clinical study, both of which were conducted in subjects with paediatric GHD, and both of which compared the efficacy and safety of once-weekly Ngenla with Genotropin (somatropin), a recombinant human growth hormone for injection administered once-daily. In both studies, Ngenla showed comparable efficacy to Genotropin in the primary endpoint of annual height velocity at 12 months. Ngenla was generally well tolerated in both studies, with comparable safety to that of Genotropin administered once-daily with respect to the types, numbers and severity of the adverse events observed between the treatment arms.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!